Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib in Malignant Mesothelioma
NCT00025207Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2001
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib in malignant mesothelioma, sponsored by National Cancer Institute. Started Sep 2001; status: completed.
02
Drugs
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT00025207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025207.